Activity Preview


Challenging Treatment Issues in Schizophrenia

Activity Type:

  • On Demand

Release Date: 8/20/2015

Expiration Date: 8/20/2018

  • AMA PRA Category 1: 2
  • Participation: 2

Access Activity


Schizophrenia is a complex illness with a substantial severity in symptoms at its outset and challenges to obtain the best outcomes. As psychiatrists and mental health professionals engage in planning treatment approaches, much of the textbook and clinical trial studies focus on very straight-forward issues in treatment of psychosis, but may not describe approaches to complexities of the disease. In this course, the authors describe and focus on the complexities of treatment issues in order for the attendees to learn about the assessment and treatment of difficult dilemmas in order to lead to better outcomes. Dr. Thomas McGlashan has performed substantial and leading research in the prodromal phase of schizophrenia (now known as attenuated psychosis syndrome in DSM5). His work addresses tools to approach the assessment and identification of the prodrome in ways that can help clinicians identify those at high risk. He has performed very informative clinical trials and will discuss their impact on the field. Further, he will address the models of comprehensive care and the impact of early intervention. The publications of medication treatments show statistically significant impact of antipsychotic medications on psychotic symptoms, but clinicians in the field of treating people with schizophrenia are aware that patients are not always consistent or adherent to the treatment plan. Dr. Peter Weiden will describe studies he has conducted examining the impact of cognitive behavior techniques and the role of long-acting injectable medication. The combination of these approaches can lead to more successful outcomes. Dr. Douglas Ziedonis will approach the very concerning issue of comorbid substance use in psychiatry. This is a needed area of education as so many studies excluded research candidates for schizophrenia studies who have addictions or abuse. Further, this is a complex arena as drugs of abuse for psychotic people are not only addicting, but may be psychotomimetic. Dr. Peter Buckley's background includes major approaches to dealing with the most seriously ill psychiatric patients. In summary, there are a number of very challenging treatment issues in the management of schizophrenia. This course is designed to address and describe the issues for the attendees understanding and to provide the latest approaches for these issues.

**This content was captured at the 2014 APA Annual Meeting


  • General Member - $30.00
  • Resident-Fellow Member - Free
  • Medical Student Member - $30.00
  • Non-Member - $60.00

Educational Objectives

  • Develop a treatment plan for the Attenuated Psychosis Syndrome (Prodrome) patients 
  • Assess and extend interventions to the poorly responding patients with schizophrenia 
  • Understand treatment of patients with schizophrenia who have issues with addictions and adherence 

Target Audience

Residents/Fellows and Psychiatrists

Estimated Time to Complete

2 Hours

How to Earn Credit

Participants who wish to earn AMA PRA Category 1 Credit ™ or a certificate of participation may do so by completing all sections of the course including the evaluation. A multiple choice quiz is provided based on the content. A passing score of 60% must be achieved. Retakes are available for the test. After evaluating the program, course participants will be provided with an opportunity to claim hours of participation and print an official CME certificate showing the date of completion and hours earned. 

Continuing Education Credit

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The APA designates this enduring material for a maximum of 2 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Faculty and Planner Disclosures


  • S. Charles Schulz, M.D., University of Minnesota | Disclosure: Consultant/Advisory Board - Eli Lilly and Company|Genentech | Grant/Research Support - AstraZeneca Pharmaceuticals | Myriad Pharmaceuticals | Otsuka Pharmaceuticals | Other - Genentech Consultant
  • Peter F. Buckley, M.D., Georgia Regents University | Disclosure: Reports no financial relationships with commercial interests


  • Thomas McGlashan, M.D., Yale School of Medicine | Disclosure: Reports no financial relationships with commercial interests
  • Peter J. Weiden, M.D., University of Illinois at Chicago | Disclosure: Consultant/Advisory Board - Delpor Technology | Johnson & Johnson | Lundbeck | Otsuka Pharmaceuticals | Merck & Co. | Novartis Pharmaceuticals Corporation | Sunovion Pharmaceuticals Inc. | Roche | Reckitt Benckiser Pharmaceuticals | Grant/Research Support - Roche | Johnson & Johnson | Merck & Co. | Novartis Pharmaceuticals Corporation | Sunovion Pharmaceuticals Inc. | Neurocrine Biosciences Inc. | Speakers Bureau/Speaker Honoraria - Johnson & Johnson | Merck & Co. | Novartis Pharmaceuticals Corporation | Sunovion Pharmaceuticals Inc. | Stock/Other financial relationship - Delpor Technology
  • Douglas M. Ziedonis, M.D., M.P.H., Umass Medical School/Umass Memorial Health Care | Disclosure: Reports no financial relationships with commercial interests
  • Peter F. Buckley, M.D., Georgia Regents University | Disclosure: Reports no financial relationships with commercial interestse

Program Planners:

  • Tristan Gorrindo, M.D., Director of Education, American Psychiatric Association | Disclsoure: Reports no financial relationships with commercial interests
  • Ricardo Juarez, Associate Director, Office of International Affairs, American Psychiatric Association | Disclosure: Reports no financial relationships with commercial interests

Hardware/Software Requirements

Hardware/Software Specifications:
This internet-based CME activity is best experienced using Internet Explorer 8+, Mozilla Firefox 3+, Safari 4+. This Web site requires that JavaScript and session cookies be enabled. Certain activities may require additional software to view multimedia, presentation, or printable versions of the content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Adobe Acrobat, Microsoft PowerPoint, and Windows Media Player.

Optimal System Configuration:
Flash Player: Adobe Flash Player 10.1+
Browser: Firefox 3+, Internet Explorer 8.0+, Safari 4.0+, or Google Chrome 7.0+
Operating System: Windows XP+ or Mac OS X 10.4+
Internet Connection: 1 Mbps or higher

Minimum Requirements:
Windows PC:
500-MHz Pentium II; Windows XP or higher; 128 MB RAM; Video Card at least 64MB of video memory; Sound Card at least 16-bit; Macromedia Flash Player 10 or higher, audio playback with speakers for programs with video content; Firefox 1.1+, Internet Explorer 7.0+, Safari 1.0+, Google Chrome, or Opera
Mac OS X 10.3 or higher with latest updates installed; 1.83MHz Intel Core Duo or faster; RAM: 128MB or more; Video Card: at least 64MB of video memory; Sound Card: at least 16-bit

For assistance: Contact for questions about this course | Contact for technical assistance

Access Activity